ASCO Myeloma Information

Myeloma Information

• December 11, 2015
• Reading time: 1 minute

This article is a summary translated from ASCO 2015 regarding research on elotuzumab combination therapy for relapsed multiple myeloma. Current Phase III study results show that using elotuzumab and dexamethasone can effectively increase median overall survival by five months. This was presented by Dr. Julie M. Vose, the then President-elect of ASCO.

Elotuzumab is a monoclonal antibody that targets SLAMF7, a protein found on the surface of myeloma cells and on natural killer (NK) cells within the immune system. Elotuzumab directly tags the myeloma cells, which enhances the NK cells' ability to target and destroy them. (Note: Elotuzumab does not increase the number or strength of NK cells but helps them identify and attack the myeloma cells more effectively).

The trial involved 646 participants. For more detailed information, including data and experimental methods, please refer to the following link:

http://meetinglibrary.asco.org/content/144025-156

Myeloma

• Immunotherapy
• Clinical Trial Drugs
  • (Lung Cancer) Phase II Clinical Trial Results for Topotecan and Topotecan + Berzosertib
  • (Lung Cancer) Is Enhertu Effective for HER2-Mutated Non-Small Cell Lung Cancer?
  • (Lung Cancer) Is the Anti-B7-H3 Antibody-Drug Conjugate DS-7300 Effective?

Medical Supporter Formerly certified by Japan's Ministry of Foreign Affairs and METI as an international medical visa guarantor (B-066).

Figure 1

Figure 2

Figure 3

Figure 4